美国联合医疗公司宣布，将为旗下药物Tyvaso的补充新药申请（sNDA）寻求优先审评资格。该公司计划于今年夏季结束前向美国食品药品监督管理局（FDA）正式提交该项申请。
优先审评资格将加速FDA对Tyvaso申请的审批流程，若获批准，有望使该药物更早惠及患者。此次申报标志着公司在拓展Tyvaso适应症方面迈出关键一步。
美国联合医疗公司宣布，将为旗下药物Tyvaso的补充新药申请（sNDA）寻求优先审评资格。该公司计划于今年夏季结束前向美国食品药品监督管理局（FDA）正式提交该项申请。
优先审评资格将加速FDA对Tyvaso申请的审批流程，若获批准，有望使该药物更早惠及患者。此次申报标志着公司在拓展Tyvaso适应症方面迈出关键一步。
Disclaimer: Investing carries risk. This is not financial advice. The above content should not be regarded as an offer, recommendation, or solicitation on acquiring or disposing of any financial products, any associated discussions, comments, or posts by author or other users should not be considered as such either. It is solely for general information purpose only, which does not consider your own investment objectives, financial situations or needs. TTM assumes no responsibility or warranty for the accuracy and completeness of the information, investors should do their own research and may seek professional advice before investing.